MA45430A - Analogues de célastrol - Google Patents

Analogues de célastrol

Info

Publication number
MA45430A
MA45430A MA045430A MA45430A MA45430A MA 45430 A MA45430 A MA 45430A MA 045430 A MA045430 A MA 045430A MA 45430 A MA45430 A MA 45430A MA 45430 A MA45430 A MA 45430A
Authority
MA
Morocco
Prior art keywords
celastrol
analogues
celastrol analogues
Prior art date
Application number
MA045430A
Other languages
English (en)
French (fr)
Inventor
Yanbing Ding
Ralph Mazitschek
Kaisheng Shen
Original Assignee
Erx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erx Pharmaceuticals Inc filed Critical Erx Pharmaceuticals Inc
Publication of MA45430A publication Critical patent/MA45430A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Filters (AREA)
MA045430A 2015-10-23 2016-10-21 Analogues de célastrol MA45430A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245356P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
MA45430A true MA45430A (fr) 2019-05-01

Family

ID=58558149

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045430A MA45430A (fr) 2015-10-23 2016-10-21 Analogues de célastrol

Country Status (8)

Country Link
US (3) US10662218B2 (enExample)
EP (1) EP3364956A4 (enExample)
JP (3) JP7034078B2 (enExample)
CN (2) CN119241632A (enExample)
AU (3) AU2016342375B2 (enExample)
BR (1) BR112018008103A2 (enExample)
MA (1) MA45430A (enExample)
WO (1) WO2017070615A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
WO2017180998A2 (en) 2016-04-15 2017-10-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
WO2017214709A1 (en) * 2016-06-15 2017-12-21 NOISEUX, Nicolas Reagents, compositions and methods for improving viability and function of cells, tissues and organs
CN108026142B (zh) * 2016-07-04 2022-07-08 艾凯奇(厦门)生物科技有限公司 孤儿核受体Nur77的配体及其用途
CN109705187B (zh) * 2019-01-29 2021-08-20 石家庄学院 一种雷公藤红素衍生物及其制备方法与应用
CN112094313B (zh) * 2019-06-17 2023-07-04 中国科学院上海药物研究所 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途
CN112110977B (zh) * 2019-06-21 2022-02-25 中国科学院上海药物研究所 一类雷公藤红素衍生物、其制备方法及用途
CA3163593A1 (en) 2020-01-15 2021-07-22 Guangrong Zheng Therapeutic agents and methods of treatment
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
US12673106B2 (en) 2020-08-28 2026-07-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof
CN115677812B (zh) * 2022-01-18 2023-12-15 聊城大学 一类雷公藤红素衍生物及其制备方法与应用
US20250375401A1 (en) * 2022-06-21 2025-12-11 Seoul National University R&Db Foundation Pharmaceutical composition containing demethylzeylasteral for prevention or treatment of diseases caused by muscle loss
IL317983A (en) * 2022-07-15 2025-02-01 Celloram Inc History of Celestrol
EP4618998A1 (en) * 2022-11-17 2025-09-24 ERX Pharmaceuticals Inc. Celastrol salts, crystalline forms, and uses thereof
US20260191807A1 (en) * 2022-11-17 2026-07-09 Erx Pharmaceuticals Inc. Compositions and methods for treatment of prader-willi syndrome
WO2025106760A1 (en) * 2023-11-16 2025-05-22 Erx Pharmaceuticals Corporation Intranasal formulations of celastrol
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
FR2875913A1 (fr) 2004-09-29 2006-03-31 Sea On Line Sa Systeme d'alerte anti-collision installe a bord d'un vehicule marin et procede d'analyse anti-collision
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
CN101686951A (zh) 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CA2808359C (en) * 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
EA201492184A1 (ru) 2012-05-25 2015-07-30 Берг Ллк Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
CA2874631C (en) 2012-05-25 2022-08-30 S.P.M. Flow Control, Inc. Apparatus and methods for evaluating systems associated with wellheads
CN111529535A (zh) * 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
BR112016021985B1 (pt) * 2014-03-26 2022-08-30 The General Hospital Corporation Formulação farmacêutica
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
WO2018125812A1 (en) 2017-01-02 2018-07-05 Gauss Surgical, Inc. Tracking surgical items with prediction of duplicate imaging of items

Also Published As

Publication number Publication date
RU2018118633A (ru) 2019-11-25
BR112018008103A2 (pt) 2018-11-06
US20240190911A1 (en) 2024-06-13
JP2022017473A (ja) 2022-01-25
JP7339992B2 (ja) 2023-09-06
CN108601751A (zh) 2018-09-28
US20210061851A1 (en) 2021-03-04
AU2024201504A1 (en) 2024-03-28
AU2022204238A1 (en) 2022-07-07
JP7034078B2 (ja) 2022-03-11
JP2023164877A (ja) 2023-11-14
EP3364956A4 (en) 2019-05-01
JP2018531289A (ja) 2018-10-25
US10662218B2 (en) 2020-05-26
WO2017070615A1 (en) 2017-04-27
AU2022204238B2 (en) 2023-12-14
US20180362575A1 (en) 2018-12-20
AU2016342375B2 (en) 2022-03-17
CA3002924A1 (en) 2017-04-27
RU2018118633A3 (enExample) 2020-02-17
CN119241632A (zh) 2025-01-03
EP3364956A1 (en) 2018-08-29
US11753436B2 (en) 2023-09-12
AU2016342375A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
EP3364956A4 (en) ANALOG OF CELASTROL
EP3360001A4 (en) HEAD-MOUNTED DISPLAY DEVICE
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3305788T3 (da) Janus-kinase-hæmmer
DK3331529T3 (da) Muskarinagonister
EP3290364A4 (en) Conveyor belt wear monitoring system
EP3395868A4 (en) STRUCTURE
DK3310450T3 (da) Olie-vand-separator
EP3337164A4 (en) HEAD-MOUNTED DISPLAY
DK3394281T3 (da) Gærcelle
EP3297518B1 (en) VIDEO LARYNGOSCOPES
DK3270930T3 (da) Præeklampsi
EP3343603A4 (en) STRUCTURE
EP3363322A4 (en) Hair extender
DK3292136T3 (da) Penicillin-g-acylaser
DK3274482T3 (da) Stenborsknop
EP3390373C0 (en) DOTA SUMMARY
EP3548009A4 (en) POLYMANANOPARTICLE
DE112015006486A5 (de) Inkubationsrinne
EP3377179A4 (en) DEUTERED EPI-743
HUE054584T2 (hu) Maropitant készítmény
EP3334447A4 (en) CCK2R-drug conjugates